DE69630324D1 - Verfahren und Kristallformen von 2-Methylthienobenzodiazepinen - Google Patents

Verfahren und Kristallformen von 2-Methylthienobenzodiazepinen

Info

Publication number: DE69630324D1
Authority: DE; Germany
Prior art keywords: methylthienobenzodiazepines; crystal forms; crystal; forms
Prior art date: 1995-03-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE69630324T

Other languages

English (en)

Other versions

DE69630324T2 (de

Inventor

Charles Arthur Bunnell

Barry Arnold Hendriksen

Samuel Dean Larsen

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Eli Lilly and Co Ltd

Eli Lilly and Co

Original Assignee

Eli Lilly and Co Ltd

Eli Lilly and Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-03-24

Filing date

1996-03-22

Publication date

2003-11-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23621056&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69630324(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-03-22 Application filed by Eli Lilly and Co Ltd, Eli Lilly and Co filed Critical Eli Lilly and Co Ltd

2003-11-13 Application granted granted Critical

2003-11-13 Publication of DE69630324D1 publication Critical patent/DE69630324D1/de

2004-07-29 Publication of DE69630324T2 publication Critical patent/DE69630324T2/de

2016-03-23 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Medicinal Preparation (AREA)

DE69630324T 1995-03-24 1996-03-22 Verfahren und Kristallformen von 2-Methylthienobenzodiazepinen Expired - Lifetime DE69630324T2 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US40956695A	1995-03-24	1995-03-24
US409566		1995-03-24

Publications (2)

Publication Number	Publication Date
DE69630324D1 true DE69630324D1 (de)	2003-11-13
DE69630324T2 DE69630324T2 (de)	2004-07-29

Family

ID=23621056

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
DE69614426T Expired - Lifetime DE69614426T2 (de)	1995-03-24	1996-03-22	Kristallformen eines Thieno(2,3-B)(1,5)benzodiazepinderivates und Verfahren zu deren Herstellung
DE69630324T Expired - Lifetime DE69630324T2 (de)	1995-03-24	1996-03-22	Verfahren und Kristallformen von 2-Methylthienobenzodiazepinen
DE19681286T Withdrawn DE19681286T1 (de)	1995-03-24	1996-03-22	Neue Kristallform von Olanzapin
DE69636313T Expired - Lifetime DE69636313T2 (de)	1995-03-24	1996-03-22	Verwendung von Kristallformen von 2-Methylthienobenzodiazepinen

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DE69614426T Expired - Lifetime DE69614426T2 (de)	1995-03-24	1996-03-22	Kristallformen eines Thieno(2,3-B)(1,5)benzodiazepinderivates und Verfahren zu deren Herstellung

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
DE19681286T Withdrawn DE19681286T1 (de)	1995-03-24	1996-03-22	Neue Kristallform von Olanzapin
DE69636313T Expired - Lifetime DE69636313T2 (de)	1995-03-24	1996-03-22	Verwendung von Kristallformen von 2-Methylthienobenzodiazepinen

Country Status (48)

Country	Link
US (1)	US5736541A (de)
EP (3)	EP0733635B1 (de)
JP (1)	JPH11502535A (de)
KR (1)	KR100399688B1 (de)
CN (1)	CN1065536C (de)
AP (1)	AP828A (de)
AR (2)	AR002719A1 (de)
AT (4)	ATE331719T1 (de)
AU (1)	AU706471B2 (de)
BG (1)	BG62619B1 (de)
BR (1)	BR9607790A (de)
CA (1)	CA2214005C (de)
CH (1)	CH690579A5 (de)
CO (1)	CO4650278A1 (de)
CZ (1)	CZ292688B6 (de)
DE (4)	DE69614426T2 (de)
DK (4)	DK0733635T3 (de)
EA (1)	EA000149B1 (de)
EE (1)	EE03489B1 (de)
EG (1)	EG23659A (de)
ES (3)	ES2208220T3 (de)
FI (1)	FI973750L (de)
GB (1)	GB2313835B (de)
HU (1)	HU224989B1 (de)
IL (1)	IL117610A (de)
IS (1)	IS1896B (de)
LT (1)	LT4349B (de)
LU (1)	LU90096B1 (de)
LV (1)	LV12018B (de)
MY (1)	MY114701A (de)
NO (1)	NO314663B1 (de)
NZ (1)	NZ306110A (de)
OA (1)	OA10510A (de)
PA (1)	PA8353701A1 (de)
PE (1)	PE44897A1 (de)
PL (1)	PL183723B1 (de)
PT (3)	PT1095941E (de)
RO (1)	RO118872B1 (de)
SE (1)	SE9703205L (de)
SI (4)	SI9620040B (de)
SK (1)	SK284143B6 (de)
SV (1)	SV1996000031A (de)
TR (1)	TR199701017T1 (de)
TW (2)	TW513432B (de)
UA (1)	UA44765C2 (de)
WO (1)	WO1996030375A1 (de)
YU (1)	YU49478B (de)
ZA (2)	ZA962342B (de)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EG23659A (en) *	1995-03-24	2007-03-26	Lilly Co Eli	Process and crystal forms of methyl-thieno-benzodiazepine
WO1997011700A1 (en) *	1995-09-29	1997-04-03	Eli Lilly And Company	Method for treating a tic disorder
BR9708181A (pt) *	1996-03-11	1999-07-27	Lilly Co Eli	Método parsa tratamento da insônia
UA57727C2 (uk) *	1996-03-11	2003-07-15	Елі Ліллі Енд Компані	Спосіб лікування надмірної агресивності
PL329221A1 (en) *	1996-03-25	1999-03-15	Lilly Co Eli	Method of relieving hemicrania pains
JP2000507546A (ja) *	1996-03-25	2000-06-20	イーライ・リリー・アンド・カンパニー	麻酔方法
NZ332039A (en) *	1996-03-25	2000-06-23	Lilly Co Eli	Method for treating pain using olanzapine and NSAIDs
CZ298198A3 (cs) *	1996-03-25	1999-06-16	Eli Lilly And Company	Farmaceutický přípravek
TR199900639T2 (xx) *	1996-09-23	1999-06-21	Eli Lilly And Company	Olanzapin dihidrat D.
ZA978515B (en) *	1996-09-23	1999-03-23	Lilly Co Eli	Intermediates and process for preparing olanzapine
WO1998046596A1 (en) *	1997-04-15	1998-10-22	Eli Lilly And Company	Method for providing neuro-protective effects
ZA982917B (en) *	1997-04-15	1999-10-06	Lilly Co Eli	Method for treating cerebral focal stroke.
US20030022889A1 (en) *	1997-04-15	2003-01-30	Bymaster Franklin P.	Method for providing neuro-protective effects
DK1155696T3 (da) *	1997-04-15	2004-07-12	Lilly Co Eli	Anvendelse af olanzapin til fremstillingen af et medikament til neurobeskyttelse
USRE43932E1 (en)	1997-07-18	2013-01-15	Novartis Ag	Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
US6617321B2 (en) *	1997-09-30	2003-09-09	Eli Lilly And Company	2-methyl-thieno-benzodiazepine formulation
CZ302367B6 (cs) *	1998-09-30	2011-04-13	Eli Lilly And Company	2-Methylthienobenzodiazepinový prípravek
FR2802101B1 (fr)	1999-12-10	2003-02-28	Aventis Pharma Sa	Association de cymemazine et d'un neuroleptique atypique
US7022698B2 (en)	1999-12-28	2006-04-04	U & I Pharmaceuticals, Ltd.	Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
US6348458B1 (en)	1999-12-28	2002-02-19	U & I Pharmaceuticals Ltd.	Polymorphic forms of olanzapine
EP1246827B1 (de) *	1999-12-28	2005-04-13	Cipla Limited	Neue polymorphe formen von olanzapin
IL154688A0 (en) *	2000-08-31	2003-09-17	Reddys Lab Ltd Dr	Hydrates of olanzapine and processes for the preparation thereof
WO2002019998A2 (en) *	2000-09-08	2002-03-14	Eli Lilly And Company	A method of treating weight gain associated with atypical antipsychotic use
US6740753B2 (en)	2001-01-04	2004-05-25	Geneva Pharmaceuticals, Inc.	Olanzapine crystal modification
EP1440074A1 (de) *	2001-10-29	2004-07-28	Dr. Reddy's Laboratories Ltd.	Olanzapin dihydrat-ii, verfahren zu ihrer herstellung und ihre anwendung
AU2002367119A1 (en) *	2001-12-24	2003-07-15	Sun Pharmaceutical Industries Limited	Crystalline form I of 2-methyl-4-(4-methyl-1-piperazinyl) 10H thieno [2,3-b][1,5]benzodiazepine
US7790905B2 (en) *	2002-02-15	2010-09-07	Mcneil-Ppc, Inc.	Pharmaceutical propylene glycol solvate compositions
US7927613B2 (en) *	2002-02-15	2011-04-19	University Of South Florida	Pharmaceutical co-crystal compositions
US20050025791A1 (en) *	2002-06-21	2005-02-03	Julius Remenar	Pharmaceutical compositions with improved dissolution
US20100311701A1 (en) *	2002-02-15	2010-12-09	Transform Pharmaceuticals, Inc	Pharmaceutical Co-Crystal Compositions
WO2004089313A2 (en) *	2003-04-01	2004-10-21	Transform Pharmaceuticals, Inc.	Novel olanzapine forms and related methods of treatment
AU2003217676B2 (en)	2002-02-22	2009-06-11	Takeda Pharmaceutical Company Limited	Active agent delivery systems and methods for protecting and administering active agents
CA2477923C (en) *	2002-03-01	2021-02-23	University Of South Florida	Multiple-component solid phases containing at least one active pharmaceutical ingredient
PL196814B1 (pl)	2002-05-17	2008-02-29	Inst Farmaceutyczny	Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty
US7297789B2 (en)	2002-05-31	2007-11-20	Sandoz, Inc.	Process of preparation of olanzapine form I
SI21270A (sl)	2002-07-15	2004-02-29	Krka, Tovarna Zdravil, D.D., Novo Mesto	Kristalne oblike olanzapina in postopki za njihovo pripravo
PL202856B1 (pl) *	2002-12-20	2009-07-31	Adamed Spo & Lstrok Ka Z Ogran	Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny
US7323459B2 (en)	2002-12-24	2008-01-29	Teva Pharmaceutical Industries Ltd.	Crystal forms, methods for their preparation and method for preparation of olanzapine
US8183290B2 (en)	2002-12-30	2012-05-22	Mcneil-Ppc, Inc.	Pharmaceutically acceptable propylene glycol solvate of naproxen
ES2232332T3 (es) *	2003-03-12	2007-08-16	Teva Pharmaceutical Industries Ltd	Composiciones farmaceuticas estables de desloratadina.
US20060135547A1 (en) *	2003-03-12	2006-06-22	Toth Zoltan G	Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
GB0314149D0 (en) *	2003-06-18	2003-07-23	Generics Uk Ltd	Novel amorphous forms
GB0326148D0 (en)	2003-11-10	2003-12-17	Lilly Co Eli	Morpholine derivatives
CA2546200A1 (en) *	2003-11-18	2005-06-02	3M Innovative Properties Company	Olanzapine containing transdermal drug delivery compositions
WO2005063771A1 (en) *	2003-12-22	2005-07-14	Teva Pharmaceutical Industries Ltd	Methods of preparing olanzapine
US20050272720A1 (en) *	2004-01-27	2005-12-08	Rolf Keltjens	Process for making olanzapine Form I
ATE504588T1 (de)	2004-01-27	2011-04-15	Synthon Bv	Stabile salze von olanzapin
ES2253091B1 (es)	2004-07-27	2007-02-01	Inke, S.A.	Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
US7829700B2 (en)	2004-09-06	2010-11-09	Shasun Chemicals And Drugs Limited	Process for preparation of a pharmaceutically pure polymorphic form I of Olanzapine
ES2526092T3 (es) *	2004-11-16	2015-01-05	Alkermes Pharma Ireland Limited	Formulaciones de olanzapina en nanopartículas inyectables
JP4940152B2 (ja)	2005-01-05	2012-05-30	イーライリリーアンドカンパニー	パモ酸オランザピン二水和物
CZ297214B6 (cs) *	2005-02-02	2006-10-11	Zentiva, A. S.	Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby
AR053562A1 (es) *	2005-03-21	2007-05-09	Reddys Lab Ltd Dr	Proceso para la preparacion de la forma i cristalina de olanzapina
US20070021605A1 (en) *	2005-07-20	2007-01-25	Rolf Keltjens	Process and composition for making olanzapine form i
EP1919923A1 (de) *	2005-08-17	2008-05-14	Synthon B.V.	Verfahren zur herstellung von olanzapin form i
GB0522474D0 (en) *	2005-11-03	2005-12-14	Actavis Group	A pharmaceutical formulation
HUP0501046A2 (en) *	2005-11-11	2007-08-28	Egis Gyogyszergyar Nyilvanosan	Process for the preparation of olanzapine
US8222184B2 (en)	2006-03-07	2012-07-17	Ncr Corporation	UV and thermal guard
US8721202B2 (en)	2005-12-08	2014-05-13	Ncr Corporation	Two-sided thermal print switch
US8367580B2 (en)	2006-03-07	2013-02-05	Ncr Corporation	Dual-sided thermal security features
ES2279715B1 (es)	2005-12-26	2008-06-01	Laboratorios Lesvi, S.L.	Formulacion oral de olanzapina.
US7834176B2 (en)	2006-01-26	2010-11-16	Sandoz Ag	Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
US20070293479A1 (en) *	2006-05-18	2007-12-20	Osinga Niels J	Olanzapine pharmaceutical composition
US20080138409A1 (en) *	2006-09-29	2008-06-12	Osinga Niels J	Olanzapine pharmaceutical composition
US7718649B1 (en)	2006-11-10	2010-05-18	Pisgah Labs, Inc.	Physical states of a pharmaceutical drug substance
US8039461B1 (en)	2006-11-10	2011-10-18	Pisgah Laboratories, Inc.	Physical states of a pharmaceutical drug substance
PL381564A1 (pl)	2007-01-22	2008-08-04	Koźluk Tomasz Nobilus Ent	Sposób wytwarzania zasadniczo czystej odmiany polimorficznej I olanzapiny
CA2591644A1 (en) *	2007-06-14	2008-12-14	Apotex Pharmachem Inc.	Novel processes to form-i of olanzapine
US9056488B2 (en)	2007-07-12	2015-06-16	Ncr Corporation	Two-side thermal printer
US8883863B1 (en)	2008-04-03	2014-11-11	Pisgah Laboratories, Inc.	Safety of psuedoephedrine drug products
CN101735239B (zh) *	2008-11-06	2011-08-31	齐鲁制药有限公司	一种无水奥氮平晶型ii的制备方法
EP2292624A1 (de)	2009-07-20	2011-03-09	LEK Pharmaceuticals d.d.	Olanzapinreinigungsverfahren
EP3446565B1 (de)	2010-08-23	2023-11-01	Alkermes Pharma Ireland Limited	Verfahren zur behandlung von durch antipsychotika induzierter gewichtszunahme
CN102093386B (zh) *	2011-01-05	2016-06-01	浙江华海药业股份有限公司	一种制备奥兰扎平晶型ⅱ的方法
WO2012153347A2 (en)	2011-05-04	2012-11-15	Zentiva K.S.	Oral pharmaceutical composition of olanzapine form 1
CN104755928B (zh)	2012-08-21	2017-05-10	詹森药业有限公司	奥氮平的抗体及其用途
EP3581195B1 (de) *	2012-08-21	2025-10-01	Janssen Pharmaceutica NV	Antikörper gegen olanzapinhaptene und verwendung davon
ES2926662T3 (es)	2012-08-21	2022-10-27	Janssen Pharmaceutica Nv	Anticuerpos contra haptenos de risperidona y uso de los mismos
US20140206667A1 (en)	2012-11-14	2014-07-24	Michela Gallagher	Methods and compositions for treating schizophrenia
CN103848847B (zh) *	2012-12-04	2018-02-06	广东东阳光药业有限公司	一种改进制备奥氮平及其晶型ii的方法
JP6008734B2 (ja) *	2012-12-20	2016-10-19	株式会社トクヤマ	オランザピンｉｉ型結晶の製造方法
CN103145731B (zh) *	2013-02-26	2014-02-19	江苏豪森药业股份有限公司	奥氮平晶型及其制备方法和用途
KR20240130825A (ko)	2022-01-20	2024-08-29	테바 파마슈티컬스 인터내셔널 게엠베하	올란자핀, 이의 조성물 및 이의 사용 방법
LT4554562T (lt)	2023-01-10	2025-12-10	Medincell Sa	Olanzapino kompozicijos ir panaudojimo būdai

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4115568A (en) *	1974-11-26	1978-09-19	Lilly Industries Limited	Thieno[3,2-b]-[1,5]benzodiazepines
GB1548022A (en)	1976-10-06	1979-07-04	Wyeth John & Brother Ltd	Pharmaceutial dosage forms
CA1097233A (en)	1977-07-20	1981-03-10	George K. E. Gregory	Packages
US4237279A (en) *	1979-07-27	1980-12-02	Eli Lilly And Company	Crystalline 3-hydroxycephalosporin solvates
IE53696B1 (en)	1981-12-02	1989-01-18	Wyeth John & Brother Ltd	Solid shaped articles
US5039540A (en)	1989-08-14	1991-08-13	Neophore Technologies, Inc.	Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5079018A (en)	1989-08-14	1992-01-07	Neophore Technologies, Inc.	Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
GB9009229D0 (en) *	1990-04-25	1990-06-20	Lilly Industries Ltd	Pharmaceutical compounds
US5229382A (en) *	1990-04-25	1993-07-20	Lilly Industries Limited	2-methyl-thieno-benzodiazepine
CA2097016A1 (en) *	1992-05-29	1993-11-30	John Fairhurst	Pharmaceutical compounds
US5439888A (en) *	1994-03-04	1995-08-08	Eli Lilly And Company	Antithrombotic agents
US5457101A (en) *	1994-06-03	1995-10-10	Eli Lilly And Company	Thieno[1,5]benzoidiazepine use
EG23659A (en) *	1995-03-24	2007-03-26	Lilly Co Eli	Process and crystal forms of methyl-thieno-benzodiazepine

1996
- 1996-03-21 EG EG19960250A patent/EG23659A/xx active
- 1996-03-22 PT PT00203573T patent/PT1095941E/pt unknown
- 1996-03-22 DE DE69614426T patent/DE69614426T2/de not_active Expired - Lifetime
- 1996-03-22 ES ES00203573T patent/ES2208220T3/es not_active Expired - Lifetime
- 1996-03-22 DE DE69630324T patent/DE69630324T2/de not_active Expired - Lifetime
- 1996-03-22 AT AT03077455T patent/ATE331719T1/de active
- 1996-03-22 IL IL11761096A patent/IL117610A/xx not_active IP Right Cessation
- 1996-03-22 DE DE19681286T patent/DE19681286T1/de not_active Withdrawn
- 1996-03-22 AU AU54279/96A patent/AU706471B2/en not_active Ceased
- 1996-03-22 CO CO96014567A patent/CO4650278A1/es unknown
- 1996-03-22 AT AT0902196A patent/AT406771B/de not_active IP Right Cessation
- 1996-03-22 PL PL96322501A patent/PL183723B1/pl not_active IP Right Cessation
- 1996-03-22 DE DE69636313T patent/DE69636313T2/de not_active Expired - Lifetime
- 1996-03-22 DK DK96302000T patent/DK0733635T3/da active
- 1996-03-22 JP JP8529532A patent/JPH11502535A/ja not_active Ceased
- 1996-03-22 TW TW085103499A patent/TW513432B/zh not_active IP Right Cessation
- 1996-03-22 BR BR9607790A patent/BR9607790A/pt not_active IP Right Cessation
- 1996-03-22 EA EA199700262A patent/EA000149B1/ru not_active IP Right Cessation
- 1996-03-22 HU HU9802824A patent/HU224989B1/hu not_active IP Right Cessation
- 1996-03-22 UA UA97094737A patent/UA44765C2/uk unknown
- 1996-03-22 RO RO97-01761A patent/RO118872B1/ro unknown
- 1996-03-22 ZA ZA9602342A patent/ZA962342B/xx unknown
- 1996-03-22 YU YU17796A patent/YU49478B/sh unknown
- 1996-03-22 WO PCT/US1996/003917 patent/WO1996030375A1/en not_active Ceased
- 1996-03-22 CN CN96192775A patent/CN1065536C/zh not_active Expired - Lifetime
- 1996-03-22 PT PT03077455T patent/PT1445259E/pt unknown
- 1996-03-22 DK DK03077455T patent/DK1445259T3/da active
- 1996-03-22 SI SI9620040A patent/SI9620040B/sl not_active IP Right Cessation
- 1996-03-22 CH CH02245/97A patent/CH690579A5/de not_active IP Right Cessation
- 1996-03-22 SK SK1218-97A patent/SK284143B6/sk not_active IP Right Cessation
- 1996-03-22 TW TW085103500A patent/TW442488B/zh not_active IP Right Cessation
- 1996-03-22 FI FI973750A patent/FI973750L/fi unknown
- 1996-03-22 ES ES96302000T patent/ES2159346T3/es not_active Expired - Lifetime
- 1996-03-22 EP EP96302000A patent/EP0733635B1/de not_active Expired - Lifetime
- 1996-03-22 ES ES03077455T patent/ES2266719T3/es not_active Expired - Lifetime
- 1996-03-22 KR KR1019970706591A patent/KR100399688B1/ko not_active Ceased
- 1996-03-22 TR TR97/01017T patent/TR199701017T1/xx unknown
- 1996-03-22 EP EP03077455A patent/EP1445259B1/de not_active Expired - Lifetime
- 1996-03-22 ZA ZA9602344A patent/ZA962344B/xx unknown
- 1996-03-22 SI SI9630345T patent/SI0733635T1/xx unknown
- 1996-03-22 SI SI9630743T patent/SI1445259T1/sl unknown
- 1996-03-22 CA CA002214005A patent/CA2214005C/en not_active Expired - Fee Related
- 1996-03-22 EP EP00203573A patent/EP1095941B1/de not_active Expired - Lifetime
- 1996-03-22 NZ NZ306110A patent/NZ306110A/en not_active IP Right Cessation
- 1996-03-22 AT AT00203573T patent/ATE251627T1/de active
- 1996-03-22 GB GB9719819A patent/GB2313835B/en not_active Expired - Fee Related
- 1996-03-22 PE PE1996000203A patent/PE44897A1/es not_active IP Right Cessation
- 1996-03-22 AR ARP960101876A patent/AR002719A1/es unknown
- 1996-03-22 EE EE9700232A patent/EE03489B1/xx not_active IP Right Cessation
- 1996-03-22 AP APAP/P/1997/001065A patent/AP828A/en active
- 1996-03-22 PT PT96302000T patent/PT733635E/pt unknown
- 1996-03-22 MY MYPI96001085A patent/MY114701A/en unknown
- 1996-03-22 DK DK00203573T patent/DK1095941T3/da active
- 1996-03-22 LU LU90096A patent/LU90096B1/fr active
- 1996-03-22 AT AT96302000T patent/ATE204280T1/de active
- 1996-03-22 SI SI9630636T patent/SI1095941T1/xx unknown
- 1996-03-22 AR ARP960101875A patent/AR010448A1/es unknown
- 1996-03-22 CZ CZ19973000A patent/CZ292688B6/cs not_active IP Right Cessation
- 1996-05-09 SV SV1996000031A patent/SV1996000031A/es not_active Application Discontinuation
- 1996-07-25 US US08/686,989 patent/US5736541A/en not_active Expired - Lifetime
- 1996-10-18 PA PA19968353701A patent/PA8353701A1/es unknown
1997
- 1997-09-05 SE SE9703205A patent/SE9703205L/xx not_active Application Discontinuation
- 1997-09-08 LV LVP-97-163A patent/LV12018B/en unknown
- 1997-09-16 LT LT97-148A patent/LT4349B/lt not_active IP Right Cessation
- 1997-09-22 BG BG101900A patent/BG62619B1/bg unknown
- 1997-09-22 IS IS4564A patent/IS1896B/is unknown
- 1997-09-22 NO NO19974365A patent/NO314663B1/no not_active IP Right Cessation
- 1997-09-23 DK DK108997A patent/DK108997A/da not_active Application Discontinuation
- 1997-09-24 OA OA70082A patent/OA10510A/en unknown

Also Published As

Publication number	Publication date
LU90096B1 (fr)	1997-07-22
CA2214005C (en)	2001-07-03
NO314663B1 (no)	2003-04-28
SV1996000031A (es)	1998-03-27
SE9703205D0 (sv)	1997-09-05
ES2208220T3 (es)	2004-06-16
YU17796A (sh)	1999-03-04
IS1896B (is)	2003-10-20
NO974365L (no)	1997-09-22
DE69614426T2 (de)	2002-05-23
RO118872B1 (ro)	2003-12-30
AU706471B2 (en)	1999-06-17
HUP9802824A2 (hu)	1999-06-28
JPH11502535A (ja)	1999-03-02
FI973750A7 (fi)	1997-09-22
AU5427996A (en)	1996-10-16
ATE251627T1 (de)	2003-10-15
CA2214005A1 (en)	1996-10-03
SI0733635T1 (en)	2002-06-30
IL117610A (en)	2001-08-26
EP0733635A1 (de)	1996-09-25
ES2266719T3 (es)	2007-03-01
SE9703205L (sv)	1997-09-05
GB2313835A (en)	1997-12-10
ATE331719T1 (de)	2006-07-15
NZ306110A (en)	1998-09-24
TW442488B (en)	2001-06-23
AR002719A1 (es)	1998-04-29
KR19980703188A (ko)	1998-10-15
HU224989B1 (en)	2006-05-29
PA8353701A1 (es)	1998-09-18
PT1445259E (pt)	2006-10-31
DK1095941T3 (da)	2004-02-16
PT1095941E (pt)	2004-02-27
HUP9802824A3 (en)	2000-01-28
LV12018A (lv)	1998-04-20
CO4650278A1 (es)	1998-09-03
NO974365D0 (no)	1997-09-22
WO1996030375A1 (en)	1996-10-03
CN1179160A (zh)	1998-04-15
GB9719819D0 (en)	1997-11-19
LV12018B (en)	1998-09-20
EE03489B1 (et)	2001-08-15
MX9707183A (es)	1997-11-29
EP1095941A1 (de)	2001-05-02
SI1445259T1 (sl)	2006-10-31
HK1013988A1 (en)	1999-09-17
DE69630324T2 (de)	2004-07-29
SI1095941T1 (en)	2003-12-31
AT406771B (de)	2000-08-25
EG23659A (en)	2007-03-26
US5736541A (en)	1998-04-07
EP0733635B1 (de)	2001-08-16
EP1095941B1 (de)	2003-10-08
DE19681286T1 (de)	1998-04-02
UA44765C2 (uk)	2002-03-15
GB2313835B (en)	1998-09-16
CZ300097A3 (en)	1997-12-17
YU49478B (sh)	2006-05-25
PL322501A1 (en)	1998-02-02
DK108997A (da)	1997-11-12
BG101900A (en)	1999-03-31
BG62619B1 (bg)	2000-03-31
AP9701065A0 (en)	1997-10-31
AR010448A1 (es)	2000-06-28
LT4349B (lt)	1998-05-25
IL117610A0 (en)	1996-07-23
PL183723B1 (pl)	2002-07-31
BR9607790A (pt)	1998-07-07
PE44897A1 (es)	1997-10-22
EE9700232A (et)	1998-04-15
ATE204280T1 (de)	2001-09-15
KR100399688B1 (ko)	2004-02-18
DK0733635T3 (da)	2001-10-08
FI973750A0 (fi)	1997-09-22
DE69636313T2 (de)	2007-05-31
OA10510A (en)	2002-04-24
DE69636313D1 (de)	2006-08-10
EA199700262A1 (ru)	1998-02-26
LT97148A (lt)	1998-01-26
IS4564A (is)	1997-09-22
SK284143B6 (sk)	2004-10-05
DK1445259T3 (da)	2006-10-16
ATA902196A (de)	2000-01-15
EA000149B1 (ru)	1998-10-29
TW513432B (en)	2002-12-11
TR199701017T1 (xx)	1998-01-21
PT733635E (pt)	2001-12-28
ZA962342B (en)	1997-09-22
SK121897A3 (en)	1998-03-04
CH690579A5 (de)	2000-10-31
EP1445259B1 (de)	2006-06-28
AP828A (en)	2000-04-28
EP1445259A1 (de)	2004-08-11
SI9620040B (sl)	2002-02-28
DE69614426D1 (de)	2001-09-20
SI9620040A (sl)	1998-06-30
ES2159346T3 (es)	2001-10-01
CZ292688B6 (cs)	2003-11-12
MY114701A (en)	2002-12-31
FI973750L (fi)	1997-09-22
ZA962344B (en)	1997-09-22
CN1065536C (zh)	2001-05-09

Publication	Publication Date	Title
DE69630324D1 (de)	2003-11-13	Verfahren und Kristallformen von 2-Methylthienobenzodiazepinen
DE69416907D1 (de)	1999-04-15	Verfahren zum Verbinden von Elementen und Verbindungsanordnung
DE69528265D1 (de)	2002-10-24	Quarzoszillator und verfahren zu seiner einstellung
DE69411777D1 (de)	1998-08-27	Einkristall-Diamant und Verfahren zu seiner Herstellung
ATE230606T1 (de)	2003-01-15	Verfahren zur vorbeugung und behandlung von allergien
DE69633983D1 (de)	2005-01-05	Inhibitoren von mikrosomalem triglycerid-transfer-protein und verfahren
KR970707470A (ko)	1997-12-01	표지(signage) 제품 및 그 제조방법(BIGNAGE ARTICLES AND METHODS OF MAKING SAME)
DE69322575D1 (de)	1999-01-28	Verfahren und Gerät zur Wiedergabe von abgeglichenen NURB Oberflächen
ATE253116T1 (de)	2003-11-15	Verbesserte antikörper gegen ige und verfahren zur verbesserung von antikörpern
DE69422842D1 (de)	2000-03-09	Verfahren und Einrichtung zur Behandlung von Lithium
DE69632418D1 (de)	2004-06-09	Verfahren zur Trennung von HFC-32 und HFC-125
DE69403862D1 (de)	1997-07-24	Oberflächenmodifizierte Auftragseinheit und Verfahren
DE69626311D1 (de)	2003-03-27	Zusammensetzung zur behandlung von wäsche sowie verfahren hierfür
DE69327548D1 (de)	2000-02-17	Diamantkristall und Verfahren zu seiner Herstellung
DE59407163D1 (de)	1998-12-03	Verfahren und Einrichtung zur Bestimmung der Reinheit von aufbereitetem Altglas
DE69409040D1 (de)	1998-04-23	Verfahren zur Entfärbung von Alkanolaminen
DE69612564D1 (de)	2001-05-23	Verfahren zur thermischen behandlung von nicht-gasförmigem material
DE59606485D1 (de)	2001-04-05	Verfahren zur Herstellung von Poly-o-hydroxyamiden und Poly-o-mercaptoamiden
DE59606489D1 (de)	2001-04-05	Verfahren zur Herstellung von Poly-o-hydroxyamiden und Poly-o-mercaptoamiden
DE69630407D1 (de)	2003-11-20	Verwendung von reinigingsmitteln und verfahren zur flaschenreinigung
DE59606657D1 (de)	2001-05-03	Verfahren zur Herstellung von Poly-o-hydroxyamiden und Poly-o-mercaptoamiden
DE69431396D1 (de)	2002-10-24	Verfahren zur herstellung von n-tert-butyl-2-pyrazincarboxamid und n-tert-butyl-2-piperazincarboxamid
DE69629867D1 (de)	2003-10-16	Verfahren zum Zuführen und Auffangen von Lösungen
DE59606488D1 (de)	2001-04-05	Verfahren zur Herstellung von Poly-o-hydroxyamiden und Poly-o-mercaptoamiden
DE69415607D1 (de)	1999-02-11	Verfahren zur Entfärbung von Alkanolaminen

Legal Events

Date	Code	Title	Description
2004-11-04	8364	No opposition during term of opposition
2010-05-20	8328	Change in the person/name/address of the agent	Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336
2011-06-16	8328	Change in the person/name/address of the agent	Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN